For the quarter ending 2025-09-30, VERA had $8,652K increase in cash & cash equivalents over the period. -$62,039K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -80,293 | -128,225 |
| Depreciation and amortization | 129 | 204 |
| Accretion of discount and amortization of premium on debt securities, net | -1,451 | -4,421 |
| Accretion of loan exit fee and amortization of loan costs, net | 843 | 377 |
| Reduction in the carrying amount of operating lease right-of-use assets | 435 | 901 |
| Stock-based compensation | 9,745 | 17,216 |
| Payment of vt-109 license fee | 0 | 800 |
| Prepaid expense and other current assets | -606 | 4,162 |
| Other assets | 108 | -158 |
| Accounts payable | 4,793 | 5,492 |
| Accrued and other liabilities | 3,915 | 3,319 |
| Operating lease liabilities | -520 | -863 |
| Net cash used in operating activities | -61,906 | -109,204 |
| Payment of vt-109 license fee | 0 | 800 |
| Proceeds from maturities of marketable securities | - | 232,307 |
| Purchase of property and equipment | 133 | 395 |
| Purchase of marketable securities | 98,696 | 187,251 |
| Proceeds from maturities of marketable securities | 400,897 | - |
| Proceeds from sale of marketable securities | 0 | 0 |
| Net cash provided by (used in) investing activities | 69,761 | 43,861 |
| Proceeds from exercise of stock options and employee stock purchase plan | 797 | 1,997 |
| Proceeds from refinancing under loan and security agreement, net | 0 | 23,338 |
| Payment of deferred issuance costs related to unfunded loan commitments | 0 | 3,517 |
| Proceeds from short swing settlement | 0 | 0 |
| Repurchase of common stock | 0 | - |
| Proceeds from issuance of common stock in follow-on offering | 0 | 0 |
| Payment of issuance costs and underwriting fees related to follow-on offering | 0 | 0 |
| Net cash provided by financing activities | 797 | 21,818 |
| Net decrease in cash and cash equivalents | 8,652 | -43,525 |
| Cash and cash equivalents at beginning of period | 92,646 | - |
| Cash and cash equivalents at end of period | 57,773 | - |
Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc. (VERA)